Skip to main content
Log in

A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Despite the widespread use of statins and ezetimibe to decrease low-density lipoprotein cholesterol (LDL-C) levels and associated atherosclerotic cardiovascular disease (ASCVD), many patients do not achieve adequate LDL-C lowering as per the recommended American College of Cardiology (ACC)/American Heart Association (AHA) and European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines and demonstrate residual cardiovascular risk. The introduction of proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors in 2015 was a promising addition to hypercholesterolemia therapies, but their cost and subcutaneous administration has limited their use, and therefore, new affordable and patient friendly treatment strategies are crucial to help reduce ASCVD risk. Bempedoic acid, a drug currently under investigation, is a small molecule that has been shown to upregulate LDL receptors, decrease LDL-C, and reduce atherosclerotic plaque formation in hypercholesterolemic patients. Furthermore, bempedoic acid is a prodrug that becomes activated by an enzyme expressed primarily in the liver, allowing it to avoid the potential myotoxicity associated with statin therapy. The purpose of this review is to summarize the major clinical studies evaluating bempedoic acid and describe its potential addition to currently approved lipid-lowering therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019 [cited 2019 Sep 17];139:25.

  2. Sirtori CR, Yamashita S, Greco MF, Corsini A, Watts GF, Ruscica M. Recent advances in synthetic pharmacotherapies for dyslipidaemias. Eur J Prev Cardiol. 2019;06:2047487319845314.

    Google Scholar 

  3. Macchi C, Sirtori CR, Corsini A, Santos RD, Watts GF, Ruscica M. A new dawn for managing dyslipidemias: the era of RNA-based therapies. Pharmacol Res. 2019;150:104413.

    Article  CAS  PubMed  Google Scholar 

  4. Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun [Internet]. 2016. [cited 2019 Oct 11];7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133702/

  5. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Bilen O, Ballantyne CM. Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase. Curr Atheroscler Rep. 2016 [cited 2019 Sep 4];18:10.

  7. Mao Z, Li J, Zhang W. Hormonal regulation of cholesterol homeostasis. In: Cholesterol-Good, Bad and the Heart. IntechOpen; 2018.

  8. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Mach, FrançoisWindecker, StephanNibouche, Djamaleddine et al. Atherosclerosis 2019; 290:140–205

  9. Mytilinaiou M, Kyrou I, Khan M, Grammatopoulos DK, Randeva HS. Familial hypercholesterolemia: new horizons for diagnosis and effective management. Front Pharmacol [Internet]. 2018. [cited 2019 Nov 20];9. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052892/.

  10. Hammersley D, Signy M. Ezetimibe: an update on its clinical usefulness in specific patient groups. Ther Adv Chronic Dis [Internet]. 2017. [cited 2019 Oct 11];8(1):4–11. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298356/.

  11. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine [Internet]. 2015. [cited 2019 Oct 11];372(25):2387–97. Available from: https://doi.org/10.1056/NEJMoa1410489.

  12. Ramkumar S, Raghunath A, Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin. 2016;32(6):631.

    PubMed  PubMed Central  Google Scholar 

  13. Kosoglou T, Statkevich P, Johnson-Levonas A, Paolini JF, Bergman AJ, Alton KB. Ezetimibe. Clin Pharmacokinet. 2005;44(5):467–94.

    Article  CAS  PubMed  Google Scholar 

  14. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh P, Yang P, Veltri EP. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24(8):729–41.

    Article  CAS  PubMed  Google Scholar 

  15. Zetia (ezetimibe) Tablets. 2019. https://www.merck.com/product/usa/pi_circulars/z/zetia/zetia_pi.pdf. Accessed Nov 2019.

  16. Paton DM. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia. Drugs Today (Barc). 2016;52(3):183–92.

    Article  CAS  PubMed  Google Scholar 

  17. Niaspan (niacin extended-release) tablet, film coated, extended release for oral use. 2019. https://www.rxabbvie.com/pdf/niaspan.pdf. Accessed Nov 2019.

  18. Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin Lipidol 2016 [cited 2019 Sep 16];10(3):556–67.

  19. Amgen presents results highlighting the long-term safety and efficacy of Repatha® (evolocumab) in the longest duration study of a PCSK9 inhibitor to date at AHA Scientific Sessions 2018 [news release]. Amgen’s website. 2019. https://www.amgen.com/media/news-releases/2018/11/amgen-presents-results-highlighting-the-longterm-safety-and-efficacy-of-repatha-evolocumab-in-the-longest-duration-study-of-a-pcsk9-inhibitor-to-date-at-aha-scientific-sessions-2018/.

  20. Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018;278:307–14.

    Article  CAS  PubMed  Google Scholar 

  21. Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Transl Res [Internet]. 2016 [cited 2020 Feb 4];173:19–29. http://www.sciencedirect.com/science/article/pii/S193152441500345X

  22. Macchi C, Banach M, Corsini A, Sirtori C, Ferri N, Ruscica M. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels—experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiolog [Internet]. 2019 [cited 2020 Feb 4];26(9):930–49. https://doi.org/10.1177/2047487319831500.

  23. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice [Internet]. 2017 [cited 2019 Sep 17];23(Supplement 2):1–87.

  24. Esperion | esperion-announces-us-fda-acceptance-new-drug-applications-ndas. (2019). https://www.esperion.com/investors-media/news-releases/news-release-details/esperion-announces-us-fda-acceptance-new-drug-applications-ndas/. Accessed 12 Nov 2019

  25. Ference BA, Ray KK, Catapano AL, Ference TB, Burgess S, Neff DR, et al. Mendelian randomization study of ACLY and cardiovascular disease. New Engl J Med [Internet]. 2019 [cited 2020 Feb 3];380(11):1033–42. https://doi.org/10.1056/NEJMoa1806747

  26. Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR. PCSK9 inhibition and inflammation: a narrative review. Atherosclerosis. 2019;288:146–55.

    Article  CAS  PubMed  Google Scholar 

  27. Pinkosky S et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J. Lipid Res 2013;54:(1) 134–151. First Published on November 1, 2012, https://doi.org/10.1194/jlr.m030528

  28. ClinicalTrials.gov. A multiple ascending dose study of ETC-1002 in subjects with mild dyslipidemia. 2019. https://clinicaltrials.gov/ct2/show/NCT01105598. Accessed Oct 2019.

  29. Esperion Therapeutics, Inc. Annual report for the fiscal year ended December 31, 2014 filed with the US Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1434868/000104746915001908/a2223469z10-k.htm#fa19801_esperion_therapeutics,_inc._in__esp02383. Accessed 25 Feb 2020

  30. Esperion Therapeutics, Inc. Annual report filed with the US Securities and Exchange Commission on May 14, 2013. https://www.sec.gov/Archives/edgar/data/1434868/000104746913006083/a2214660zs-1.htm. Accessed 25 Feb 2020

  31. ClinicalTrials.gov. A multiple ascending dose study of ETC-1002 in healthy subjects. 2019. https://clinicaltrials.gov/ct2/show/NCT01485146. Accessed Oct 2019.

  32. Ballantyne CM, Davidson MH, MacDougall DE, Bays HE, DiCarlo LA, Rosenberg NL, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013 [cited 2019 Sep 11];62(13):1154–62.

  33. ClinicalTrials.gov. Evaluation of ETC-1002 in patients with hypercholesterolemia and hypertension. 2019. https://clinicaltrials.gov/ct2/show/NCT02178098. Accessed Oct 2019.

  34. Thompson PD, Rubino J, Janik MJ, MacDougall DE, McBride SJ, Margulies JR, et al. Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015 [cited 2019 Sep 11];9(3):295–304.

  35. ClinicalTrials.gov. A study of the safety, pharmacokinetic drug interaction and efficacy of ETC-1002 and atorvastatin in subjects with hypercholesterolemia. 2019. https://clinicaltrials.gov/ct2/show/study/NCT01779453. Accessed Oct 2019.

  36. ESPERION|Esperion therapeutics announces positive top-line results from phase 2 clinical study of ETC-1002 as an add-on to statin therapy in patients with hypercholesterolemia. Esperion Website: 2019. https://www.esperion.com/investors-media/press-releases/?request=aHR0cHM6Ly9lc3Blcmlvbi5nY3Mtd2ViLmNvbS8vbmV3cy1yZWxlYXNlcy9uZXdzLXJlbGVhc2UtZGV0YWlscy9lc3Blcmlvbi10aGVyYXBldXRpY3MtYW5ub3VuY2VzLXBvc2l0aXZlLXRvcC1saW5lLXJlc3VsdHMtMA.

  37. Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, Robinson PL, Hanselman JC, et al. Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016 [cited 2019 Sep 6];117(12):1928–33.

  38. Gutierrez Maria J, Rosenberg Noah L, MacDougall Diane E, Hanselman Jeffrey C, Margulies Janice R, Poul S, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol–lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscl Thromb Vasc Biol. 2014;34(3):676–83. https://doi.org/10.1161/ATVBAHA.113.302677.

    Article  CAS  PubMed  Google Scholar 

  39. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. New Engl J Med [Internet]. 2019 [cited 2019 Sep 6];380(11):1022–32.

  40. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis. 2018 [cited 2019 Sep 16];277:195–203

  41. Laufs Ulrich, Banach Maciej, Mancini G. B. John, Gaudet Daniel, Bloedon LeAnne T., Sterling Lulu Ren, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Je Am Heart Assoc 2019 [cited 2019 Sep 6];8(7):e011662.

  42. Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Duell PB, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. JAMA. 2019;322(18):1780–8. https://doi.org/10.1001/jama.2019.16585.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Goldberg AC, et al. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: the CLEAR Wisdom trial. Am Coll Cardiol. 2019 [cited 2019 Oct 11] https://www.esperion.com/wp-content/themes/esperion/assets/pdfs/2019_Goldberg_Efficacy-and-Safety-of-Bempedoic-Acid-Added-to-Maximally-Tolerated-Statins-in-Patients-with-Hypercolesterolemia-and-High-Cardiovascular-Risk_The-CLEAR-Wisdom-Trial_ACC-19.pdf.

  44. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiolog. 2019 [cited 2020 Jan 29];2047487319864671. https://doi.org/10.1177/2047487319864671.

  45. ClinicalTrials.gov. Evaluation of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant treated with bempedoic acid (ETC-1002) or placebo (CLEAR Outcomes). https://clinicaltrials.gov/ct2/show/NCT02993406?term=bempedoic+acid&recrs=a&type=Intr&age=1&fund=2&draw=2&rank=1. Accessed Nov 2019.

  46. Zagelbaum NK, Yandrapalli S, Nabors C, Frishman WH. Bempedoic acid (ETC-1002): ATP citrate lyase inhibitor review of a first-in-class medication with potential benefit in statin-refractory cases. Cardiol Rev. 2019;27(1):49–56.

    Article  PubMed  Google Scholar 

  47. Nexletol® (bempedoic acid). Prescribing information. Esperion Therapeutics, Inc. February 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf. Accessed 25 Feb 2020.

  48. Nexlizet® (bempedoic acid and ezetimibe). Prescribing information. Esperion Therapeutics, Inc. February 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211617s000lbl.pdf. Accessed 6 Mar 2020.

Download references

Funding

No external funding was used in the preparation of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rebecca F. Goldfaden.

Ethics declarations

Conflict of interest

Stephanie Niman, Khyatiben Rana, Jessica Reid, Mae Sheikh-Ali, Todd Lewis, Rushab Choksi, and Rebecca Goldfaden declare that they have no potential conflicts of interest that might be relevant to the contents of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niman, S., Rana, K., Reid, J. et al. A Review of the Efficacy and Tolerability of Bempedoic Acid in the Treatment of Hypercholesterolemia. Am J Cardiovasc Drugs 20, 535–548 (2020). https://doi.org/10.1007/s40256-020-00399-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-020-00399-w

Navigation